脐针治疗腹泻型肠易激综合征疗效及对脑肠肽的影响

表4 正常志愿者组及2组患者治疗前后脑肠肽指标(n = 30, mean±SD)

组别	观测时点	5-HT (ng/mL)	CGRP (pg/mL)	NO (μmol/L)	SP (pg/mL)	VIP (pg/mL)
正常组		64.68±5.09	41.49±1.05	47.17±1.33	85.60±4.33	61.60±3.97
脐针组	治疗前	240.7±17.74a	60.13±1.59a	61.58±1.81a	135.4±3.40a	119.9±3.29a
	治疗后	106.4±6.46b	42.97±1.31b	50.13±1.41b	89.37±2.83b	86.67±3.28b
益生菌组	治疗前	176.7±17.15a	55.66±1.87a	57.42±1.54a	122.1±5.51a	108.9±5.26a
	治疗后	80.42±5.41bc	44.98±0.93b	48.66±1.13b	87.45±3.50b	75.71±3.85bc

^aP<0.0001, 与正常组比较, 脐针组, 益生菌组;

^bP<0.0001, 脐针组及益生菌组分别与各自治疗前比较;

^cP<0.05, 治疗后脐针组与益生菌组比较. 5-HT: 5-羟色胺; CGRP: 降钙素基因相关肽; NO: 一氧化氮; SP: P物质; VIP: 血管活性肠肽.